Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors ... View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1998-09-01

AUTHORS

JL Byrne, C Stainer, H Hyde, G Miflin, AP Haynes, EM Bessell, NH Russell

ABSTRACT

One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Here, we report the results of 55 patients with standard risk leukaemia who have undergone allogeneic transplantation using either bone marrow (n = 48) or G-CSF mobilised peripheral blood stem cells (n = 7) using CsA and MTX for GVHD prophylaxis where the dosage of CsA was regularly adjusted to maintain a trough whole blood level of 95–205 ng/ml for the first 50 days post-transplant. To achieve this level of CsA in the immediate post-transplant period, over 40% of patients required dose adjustments of CsA as a result of sub-therapeutic levels on day +1 post-transplant. The achievement of CsA levels within the therapeutic range was expedited following the introduction of a sliding scale for dose adjustment. With this regimen we have observed a low incidence of acute GVHD with only 11% of patients developing ⩾grade II disease. With a median follow-up of 66 months (range 8–132) the probability of relapse is only 6.6%. The disease-free survival probability for all patients was 72% at 5 years. These results demonstrate that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia provided that rapid attainment of therapeutic CsA levels is achieved and maintenance within a low therapeutic range may help to maximise this effect. More... »

PAGES

541-545

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396

DOI

http://dx.doi.org/10.1038/sj.bmt.1701396

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1043707730

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/9758340


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Acute Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Marrow Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cyclosporine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Therapy, Combination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Host Disease", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Graft vs Tumor Effect", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematopoietic Stem Cell Transplantation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunosuppressive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Methotrexate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Recurrence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Donors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Transplantation, Homologous", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Byrne", 
        "givenName": "JL", 
        "id": "sg:person.014313340652.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014313340652.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stainer", 
        "givenName": "C", 
        "id": "sg:person.01306721446.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306721446.32"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hyde", 
        "givenName": "H", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miflin", 
        "givenName": "G", 
        "id": "sg:person.0644121253.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644121253.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Haynes", 
        "givenName": "AP", 
        "id": "sg:person.012176706322.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012176706322.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bessell", 
        "givenName": "EM", 
        "id": "sg:person.0611001502.82", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611001502.82"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK", 
          "id": "http://www.grid.ac/institutes/grid.4563.4", 
          "name": [
            "Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Russell", 
        "givenName": "NH", 
        "id": "sg:person.0675233407.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675233407.23"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "1998-09-01", 
    "datePublishedReg": "1998-09-01", 
    "description": "One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Here, we report the results of 55 patients with standard risk leukaemia who have undergone allogeneic transplantation using either bone marrow (n\u2009=\u200948) or G-CSF mobilised peripheral blood stem cells (n\u2009=\u20097) using CsA and MTX for GVHD prophylaxis where the dosage of CsA was regularly adjusted to maintain a trough whole blood level of 95\u2013205\u2009ng/ml for the first 50 days post-transplant. To achieve this level of CsA in the immediate post-transplant period, over 40% of patients required dose adjustments of CsA as a result of sub-therapeutic levels on day +1 post-transplant. The achievement of CsA levels within the therapeutic range was expedited following the introduction of a sliding scale for dose adjustment. With this regimen we have observed a low incidence of acute GVHD with only 11% of patients developing \u2a7egrade II disease. With a median follow-up of 66 months (range 8\u2013132) the probability of relapse is only 6.6%. The disease-free survival probability for all patients was 72% at 5 years. These results demonstrate that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia provided that rapid attainment of therapeutic CsA levels is achieved and maintenance within a low therapeutic range may help to maximise this effect.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/sj.bmt.1701396", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1096890", 
        "issn": [
          "0268-3369", 
          "1476-5365"
        ], 
        "name": "Bone Marrow Transplantation", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "6", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "22"
      }
    ], 
    "keywords": [
      "allogeneic haemopoietic stem cell transplantation", 
      "haemopoietic stem cell transplantation", 
      "stem cell transplantation", 
      "host disease", 
      "recurrent leukemia", 
      "CsA levels", 
      "cell transplantation", 
      "therapeutic range", 
      "lower incidence", 
      "trough whole blood levels", 
      "immediate post-transplant period", 
      "disease-free survival probability", 
      "peripheral blood stem cells", 
      "standard-risk leukemia", 
      "therapeutic CsA levels", 
      "post-transplant period", 
      "combination of cyclosporin", 
      "dosage of CsA", 
      "probability of relapse", 
      "blood stem cells", 
      "low therapeutic range", 
      "levels of CsA", 
      "whole blood levels", 
      "sub-therapeutic levels", 
      "GVHD suppression", 
      "GVHD prophylaxis", 
      "acute GVHD", 
      "GVHD prevention", 
      "acute graft", 
      "leukemia effect", 
      "allogeneic transplantation", 
      "dose adjustment", 
      "blood levels", 
      "high risk", 
      "patients", 
      "bone marrow", 
      "G-CSF", 
      "methotrexate", 
      "short course", 
      "transplantation", 
      "graft", 
      "leukemia", 
      "disease", 
      "CsA", 
      "prophylaxis", 
      "cyclosporin", 
      "incidence", 
      "stem cells", 
      "rapid attainment", 
      "days", 
      "survival probability", 
      "GVHD", 
      "regimens", 
      "regimen", 
      "relapse", 
      "levels", 
      "suppression", 
      "marrow", 
      "months", 
      "prevention", 
      "adjustment", 
      "risk", 
      "dosage", 
      "major aim", 
      "effect", 
      "cells", 
      "aim", 
      "effective suppression", 
      "agents", 
      "years", 
      "donors", 
      "course", 
      "period", 
      "results", 
      "loss", 
      "maintenance", 
      "combination", 
      "attainment", 
      "scale", 
      "probability", 
      "optimal usage", 
      "introduction", 
      "range", 
      "usage", 
      "achievement"
    ], 
    "name": "Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis", 
    "pagination": "541-545", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1043707730"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/sj.bmt.1701396"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "9758340"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/sj.bmt.1701396", 
      "https://app.dimensions.ai/details/publication/pub.1043707730"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_298.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/sj.bmt.1701396"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/sj.bmt.1701396'


 

This table displays all metadata directly associated to this object as RDF triples.

269 TRIPLES      20 PREDICATES      130 URIs      122 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/sj.bmt.1701396 schema:about N0a1af890d0904b3aa19e18416175a861
2 N14059d94dcf841b38d39fb3c0af561ae
3 N1b8ac45a18004ab99b428e0f6c015bfa
4 N32f9c552100d4ce68d3a8c447d2429ac
5 N36d5acfef7394bfb821ecfcb4104ed4f
6 N37de6816c26643efaf222fff328309e4
7 N388aa0073eb84111b6c00e8771f18f8d
8 N395b41a02f814677ad704160fd48f238
9 N44e4f98b045c4449904ebbccd94448cc
10 N63be5709bacd4374b2fc7f62938118b5
11 N6db2464c29cd42789a2704f5b5f8783e
12 N6dd2ca607a1e462b9982b906caf38525
13 N6f7598bc6b1d4e588315049c6e9ff671
14 N728c0977688e457182f5bfc2ca1f89d8
15 N79929b05a37a4d6b80183346a8147206
16 N7f48eeb87c4845118b39c9bbf26e1d21
17 Na56dd419ed3846e1af7dcfb932014cf7
18 Na6ab55de512e4e72ae22030d885018a8
19 Nb5c09dff00ef43578898a297b8c77578
20 Nd82623566474478eae6803355b78ee65
21 anzsrc-for:11
22 anzsrc-for:1102
23 schema:author Nbf92e7978c0f4ef19c8595955de792f5
24 schema:datePublished 1998-09-01
25 schema:datePublishedReg 1998-09-01
26 schema:description One of the major aims of allogeneic haemopoietic stem cell transplantation has been the effective suppression of graft-versus-host disease (GVHD) without loss of a graft-versus-leukaemia effect. For GVHD suppression, one of the most frequently used regimens has been the combination of cyclosporin (CsA) and a short course of methotrexate (MTX) although the optimal usage of these agents remains unclear. Here, we report the results of 55 patients with standard risk leukaemia who have undergone allogeneic transplantation using either bone marrow (n = 48) or G-CSF mobilised peripheral blood stem cells (n = 7) using CsA and MTX for GVHD prophylaxis where the dosage of CsA was regularly adjusted to maintain a trough whole blood level of 95–205 ng/ml for the first 50 days post-transplant. To achieve this level of CsA in the immediate post-transplant period, over 40% of patients required dose adjustments of CsA as a result of sub-therapeutic levels on day +1 post-transplant. The achievement of CsA levels within the therapeutic range was expedited following the introduction of a sliding scale for dose adjustment. With this regimen we have observed a low incidence of acute GVHD with only 11% of patients developing ⩾grade II disease. With a median follow-up of 66 months (range 8–132) the probability of relapse is only 6.6%. The disease-free survival probability for all patients was 72% at 5 years. These results demonstrate that effective GVHD prevention with CsA and MTX can be achieved without a high risk of recurrent leukaemia provided that rapid attainment of therapeutic CsA levels is achieved and maintenance within a low therapeutic range may help to maximise this effect.
27 schema:genre article
28 schema:isAccessibleForFree false
29 schema:isPartOf N3c436ed98d9e4525aeb25d3e854e3038
30 N42f8be308b5a4277ae26ef8da9185067
31 sg:journal.1096890
32 schema:keywords CsA
33 CsA levels
34 G-CSF
35 GVHD
36 GVHD prevention
37 GVHD prophylaxis
38 GVHD suppression
39 achievement
40 acute GVHD
41 acute graft
42 adjustment
43 agents
44 aim
45 allogeneic haemopoietic stem cell transplantation
46 allogeneic transplantation
47 attainment
48 blood levels
49 blood stem cells
50 bone marrow
51 cell transplantation
52 cells
53 combination
54 combination of cyclosporin
55 course
56 cyclosporin
57 days
58 disease
59 disease-free survival probability
60 donors
61 dosage
62 dosage of CsA
63 dose adjustment
64 effect
65 effective suppression
66 graft
67 haemopoietic stem cell transplantation
68 high risk
69 host disease
70 immediate post-transplant period
71 incidence
72 introduction
73 leukemia
74 leukemia effect
75 levels
76 levels of CsA
77 loss
78 low therapeutic range
79 lower incidence
80 maintenance
81 major aim
82 marrow
83 methotrexate
84 months
85 optimal usage
86 patients
87 period
88 peripheral blood stem cells
89 post-transplant period
90 prevention
91 probability
92 probability of relapse
93 prophylaxis
94 range
95 rapid attainment
96 recurrent leukemia
97 regimen
98 regimens
99 relapse
100 results
101 risk
102 scale
103 short course
104 standard-risk leukemia
105 stem cell transplantation
106 stem cells
107 sub-therapeutic levels
108 suppression
109 survival probability
110 therapeutic CsA levels
111 therapeutic range
112 transplantation
113 trough whole blood levels
114 usage
115 whole blood levels
116 years
117 schema:name Low incidence of acute graft-versus-host disease and recurrent leukaemia in patients undergoing allogeneic haemopoietic stem cell transplantation from sibling donors with methotrexate and dose-monitored cyclosporin A prophylaxis
118 schema:pagination 541-545
119 schema:productId N637e33b421224e45a9e5f6fc61d6f72c
120 N9d18ac74b4e54a9fa388f56aa69370d9
121 Nc8776b265ae846debc6842415a2256c1
122 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043707730
123 https://doi.org/10.1038/sj.bmt.1701396
124 schema:sdDatePublished 2022-11-24T20:49
125 schema:sdLicense https://scigraph.springernature.com/explorer/license/
126 schema:sdPublisher Na50f0bed0c644943a10ea0e714863f04
127 schema:url https://doi.org/10.1038/sj.bmt.1701396
128 sgo:license sg:explorer/license/
129 sgo:sdDataset articles
130 rdf:type schema:ScholarlyArticle
131 N0a1af890d0904b3aa19e18416175a861 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Adolescent
133 rdf:type schema:DefinedTerm
134 N12dc1ec64fea450aa38f8aa96ac55c59 rdf:first sg:person.0675233407.23
135 rdf:rest rdf:nil
136 N14059d94dcf841b38d39fb3c0af561ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Tissue Donors
138 rdf:type schema:DefinedTerm
139 N1b8ac45a18004ab99b428e0f6c015bfa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Adult
141 rdf:type schema:DefinedTerm
142 N2260c1df95ae4cf6bdcd758151ffa00b rdf:first sg:person.0611001502.82
143 rdf:rest N12dc1ec64fea450aa38f8aa96ac55c59
144 N32f9c552100d4ce68d3a8c447d2429ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Middle Aged
146 rdf:type schema:DefinedTerm
147 N33623daad8d64f77b3f595ae97e54891 schema:affiliation grid-institutes:grid.4563.4
148 schema:familyName Hyde
149 schema:givenName H
150 rdf:type schema:Person
151 N36d5acfef7394bfb821ecfcb4104ed4f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Graft vs Tumor Effect
153 rdf:type schema:DefinedTerm
154 N37de6816c26643efaf222fff328309e4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Hematopoietic Stem Cell Transplantation
156 rdf:type schema:DefinedTerm
157 N388aa0073eb84111b6c00e8771f18f8d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Leukemia
159 rdf:type schema:DefinedTerm
160 N395b41a02f814677ad704160fd48f238 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Disease-Free Survival
162 rdf:type schema:DefinedTerm
163 N3c436ed98d9e4525aeb25d3e854e3038 schema:issueNumber 6
164 rdf:type schema:PublicationIssue
165 N42f8be308b5a4277ae26ef8da9185067 schema:volumeNumber 22
166 rdf:type schema:PublicationVolume
167 N44e4f98b045c4449904ebbccd94448cc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Bone Marrow Transplantation
169 rdf:type schema:DefinedTerm
170 N637e33b421224e45a9e5f6fc61d6f72c schema:name dimensions_id
171 schema:value pub.1043707730
172 rdf:type schema:PropertyValue
173 N63be5709bacd4374b2fc7f62938118b5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Drug Therapy, Combination
175 rdf:type schema:DefinedTerm
176 N6db2464c29cd42789a2704f5b5f8783e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
177 schema:name Transplantation, Homologous
178 rdf:type schema:DefinedTerm
179 N6dd2ca607a1e462b9982b906caf38525 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Cyclosporine
181 rdf:type schema:DefinedTerm
182 N6f7598bc6b1d4e588315049c6e9ff671 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Recurrence
184 rdf:type schema:DefinedTerm
185 N728c0977688e457182f5bfc2ca1f89d8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Female
187 rdf:type schema:DefinedTerm
188 N7499f01a1a8540b1995240db571f4855 rdf:first N33623daad8d64f77b3f595ae97e54891
189 rdf:rest Ndc29fa53b828448b9f91ebba9f23c754
190 N79929b05a37a4d6b80183346a8147206 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Graft vs Host Disease
192 rdf:type schema:DefinedTerm
193 N7d1ca625a5d643dd93db9517acd31a95 rdf:first sg:person.012176706322.00
194 rdf:rest N2260c1df95ae4cf6bdcd758151ffa00b
195 N7f48eeb87c4845118b39c9bbf26e1d21 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Immunosuppressive Agents
197 rdf:type schema:DefinedTerm
198 N9d18ac74b4e54a9fa388f56aa69370d9 schema:name doi
199 schema:value 10.1038/sj.bmt.1701396
200 rdf:type schema:PropertyValue
201 Na50f0bed0c644943a10ea0e714863f04 schema:name Springer Nature - SN SciGraph project
202 rdf:type schema:Organization
203 Na56dd419ed3846e1af7dcfb932014cf7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
204 schema:name Male
205 rdf:type schema:DefinedTerm
206 Na6ab55de512e4e72ae22030d885018a8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Acute Disease
208 rdf:type schema:DefinedTerm
209 Nb5c09dff00ef43578898a297b8c77578 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Methotrexate
211 rdf:type schema:DefinedTerm
212 Nbcef0a4865ac498b807e3cb29cd90338 rdf:first sg:person.01306721446.32
213 rdf:rest N7499f01a1a8540b1995240db571f4855
214 Nbf92e7978c0f4ef19c8595955de792f5 rdf:first sg:person.014313340652.77
215 rdf:rest Nbcef0a4865ac498b807e3cb29cd90338
216 Nc8776b265ae846debc6842415a2256c1 schema:name pubmed_id
217 schema:value 9758340
218 rdf:type schema:PropertyValue
219 Nd82623566474478eae6803355b78ee65 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
220 schema:name Humans
221 rdf:type schema:DefinedTerm
222 Ndc29fa53b828448b9f91ebba9f23c754 rdf:first sg:person.0644121253.44
223 rdf:rest N7d1ca625a5d643dd93db9517acd31a95
224 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
225 schema:name Medical and Health Sciences
226 rdf:type schema:DefinedTerm
227 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
228 schema:name Cardiorespiratory Medicine and Haematology
229 rdf:type schema:DefinedTerm
230 sg:journal.1096890 schema:issn 0268-3369
231 1476-5365
232 schema:name Bone Marrow Transplantation
233 schema:publisher Springer Nature
234 rdf:type schema:Periodical
235 sg:person.012176706322.00 schema:affiliation grid-institutes:grid.4563.4
236 schema:familyName Haynes
237 schema:givenName AP
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012176706322.00
239 rdf:type schema:Person
240 sg:person.01306721446.32 schema:affiliation grid-institutes:grid.4563.4
241 schema:familyName Stainer
242 schema:givenName C
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306721446.32
244 rdf:type schema:Person
245 sg:person.014313340652.77 schema:affiliation grid-institutes:grid.4563.4
246 schema:familyName Byrne
247 schema:givenName JL
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014313340652.77
249 rdf:type schema:Person
250 sg:person.0611001502.82 schema:affiliation grid-institutes:grid.4563.4
251 schema:familyName Bessell
252 schema:givenName EM
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0611001502.82
254 rdf:type schema:Person
255 sg:person.0644121253.44 schema:affiliation grid-institutes:grid.4563.4
256 schema:familyName Miflin
257 schema:givenName G
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644121253.44
259 rdf:type schema:Person
260 sg:person.0675233407.23 schema:affiliation grid-institutes:grid.4563.4
261 schema:familyName Russell
262 schema:givenName NH
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0675233407.23
264 rdf:type schema:Person
265 grid-institutes:grid.4563.4 schema:alternateName Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
266 Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
267 schema:name Department of Clinical Oncology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
268 Department of Haematology, Nottingham City Hospital and University of Nottingham, Nottingham, UK
269 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...